Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy

Both maternal respiratory syncytial virus vaccination (RSVpreF) and passive immunization with nirsevimab demonstrate robust efficacy and favorable safety, protecting newborns and infants from severe respiratory syncytial virus infections. The document provides actionable, evidence-based recommendations tailored for the Latin American healthcare context, aiming to reduce severe respiratory syncytial virus disease incidence and improve national infant health outcomes.

Authors

Institutions

Publication Details

Journal
World Journal of Pediatrics
Published
2025-11-24
DOI
https://doi.org/10.1007/s12519-025-00997-1
Citations
1
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
1.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy

Mireia Rojas, Vianey Escobar Rojas, Mercedes Robles‐Díaz, César Adrián Martínez Longoria et al.
1 citations
World Journal of Pediatrics
Respiratory viral infections research
1.35
article

Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy

Mireia Rojas, Vianey Escobar Rojas, Mercedes Robles‐Díaz, César Adrián Martínez Longoria, Patricia Saltigeral Simental, Brandon Ortiz-Casas, Carlos López Candiani, SA Lira, Rodolfo Norberto Jiménez-Juárez, Jonathan Castillo, Antonio Luévanos Velázquez, Alfonso Copto García, Martha Avilés-Robles, Juan R. Velázquez, Claudia Montesinos Ramírez, L. Ortiz, Ester Sanz López, Francisco Javier Otero Mendoza, Víctor Saúl Vital Reyes, Federico Javier Ortíz Ibarra, Zigor Campos Goenaga, Patricia Laurean Ibarra, Georgina Hernando Becerra
article en
1 citations

Abstract

Both maternal respiratory syncytial virus vaccination (RSVpreF) and passive immunization with nirsevimab demonstrate robust efficacy and favorable safety, protecting newborns and infants from severe respiratory syncytial virus infections. The document provides actionable, evidence-based recommendations tailored for the Latin American healthcare context, aiming to reduce severe respiratory syncytial virus disease incidence and improve national infant health outcomes.

World Journal of PediatricsVol. 22(1)
Mexican Social Security Institute (MX), Mexican Academy of Sciences (MX), Centro Médico Nacional La Raza (MX), Hospital Infantil de México Federico Gómez (MX), Hospital Angeles Clinica Londres (MX), Instituto de Gastroenterologia de Goiânia (BR), Mexican Association for the Clinical Research (MX), Hospital Angeles Pedregal (MX), Hospital Civil de Guadalajara (MX), Asociación Mexicana de Psicología y Desarrollo Comunitario (MX), Vietnam National Children's Hospital (VN), Mexfam (MX), Institute for Social Security and Services for State Workers (MX), Universidad Nacional Autónoma de México (MX), Tecnológico de Monterrey (MX)
Openalex Percentile: Top 14%
Respiratory viral infections research
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.